New cocktail aims to extend life in tough pancreatic cancer
NCT ID NCT05026905
First seen Jan 24, 2026 · Last updated May 16, 2026 · Updated 14 times
Summary
This study compares two chemotherapy combinations for people with metastatic pancreatic cancer that has spread. The goal is to see which combo shrinks tumors better and helps people live longer without the cancer growing. About 66 adults will receive either gemcitabine, nab-paclitaxel, and S-1/LV or gemcitabine, nab-paclitaxel, and oxaliplatin as their first treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHASE II, OPEN-LABEL, PARALLEL 2-ARM, MULTI-CENTER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
China Medical University Hospital
Taichung, 400, Taiwan
-
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, 800, Taiwan
-
National Cheng Kung University Hospital
Tainan, 600, Taiwan
-
Taichung Veterans General Hospital
Taichung, Taiwan
Conditions
Explore the condition pages connected to this study.